Siltuximab (CNTO 328): a promising option for human malignancies

Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of silt...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Runzhe, Chen, Baoan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494175/
https://www.ncbi.nlm.nih.gov/pubmed/26170629
http://dx.doi.org/10.2147/DDDT.S86438
_version_ 1782380037685641216
author Chen, Runzhe
Chen, Baoan
author_facet Chen, Runzhe
Chen, Baoan
author_sort Chen, Runzhe
collection PubMed
description Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab treatment in the future.
format Online
Article
Text
id pubmed-4494175
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44941752015-07-13 Siltuximab (CNTO 328): a promising option for human malignancies Chen, Runzhe Chen, Baoan Drug Des Devel Ther Review Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab treatment in the future. Dove Medical Press 2015-07-02 /pmc/articles/PMC4494175/ /pubmed/26170629 http://dx.doi.org/10.2147/DDDT.S86438 Text en © 2015 Chen and Chen. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Chen, Runzhe
Chen, Baoan
Siltuximab (CNTO 328): a promising option for human malignancies
title Siltuximab (CNTO 328): a promising option for human malignancies
title_full Siltuximab (CNTO 328): a promising option for human malignancies
title_fullStr Siltuximab (CNTO 328): a promising option for human malignancies
title_full_unstemmed Siltuximab (CNTO 328): a promising option for human malignancies
title_short Siltuximab (CNTO 328): a promising option for human malignancies
title_sort siltuximab (cnto 328): a promising option for human malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494175/
https://www.ncbi.nlm.nih.gov/pubmed/26170629
http://dx.doi.org/10.2147/DDDT.S86438
work_keys_str_mv AT chenrunzhe siltuximabcnto328apromisingoptionforhumanmalignancies
AT chenbaoan siltuximabcnto328apromisingoptionforhumanmalignancies

Ejemplares similares